Quoin Pharmaceuticals Ltd. (QNRX): who owns it and who trades it
As of Nov 16, 2026, QNRX insiders reported 3 purchases worth $180K in the last 12 months. The largest buyer was Denise P. Carter (Director), with $100K. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Quoin Pharmaceuticals
From the latest filingsOverall: more buying than selling. Insiders and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Insider trades
In the last 12 months, QNRX insiders reported $180K of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 31, 2026 | Denise P. Carter | Director | Purchase | 20,490 | $4.88 | $100K | Form 4 |
| Aug 31, 2026 | Sally Bridget Lawlor | CFO | Purchase | 10,244 | $4.88 | $50K | Form 4 |
| Aug 31, 2026 | Anthony James Culverwell | Director | Purchase | 6,146 | $4.88 | $30K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Denise P. Carter | Chief Operating Officer, Director | $100K | – | Aug 31, 2026 |
| Sally Bridget Lawlor | Chief Financial Officer | $50K | – | Aug 31, 2026 |
| Anthony James Culverwell | Director | $30K | – | Aug 31, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
QNRX short interest
Low short interest. Less than 0.1% of QNRX shares are sold short. Over the last 12 reports the number of shares short went down 70%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 23,705 QNRX shares were sold short, 0.0% of the shares outstanding, up 17.2% from the report before. At the average daily volume of 12,459 shares, buying them all back would take about 1.9 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 23,705 | 0.03% | +17% | 12,459 | 1.9 |
| Oct 15, 2026 | 20,231 | 0.03% | -69% | 47,994 | 1.0 |
| Sep 30, 2026 | 65,473 | 0.09% | -48% | 47,416 | 1.4 |
| Sep 15, 2026 | 126,292 | 0.18% | -76% | 152,599 | 1.0 |
| Aug 31, 2026 | 526,654 | 0.75% | +373% | 2.78M | 1.0 |
| Aug 14, 2026 | 111,299 | 0.16% | -4% | 25,136 | 4.4 |
| Jul 31, 2026 | 115,830 | – | -26% | 10,821 | 10.7 |
| Jul 15, 2026 | 156,280 | – | -40% | 39,970 | 3.9 |
| Jun 30, 2026 | 261,876 | – | +556% | 1.32M | 1.0 |
| Jun 15, 2026 | 39,939 | – | -18% | 33,565 | 1.2 |
| May 29, 2026 | 48,916 | – | -39% | 37,619 | 1.3 |
| May 15, 2026 | 79,876 | – | -7% | 14,226 | 5.6 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Quoin Pharmaceuticals company events
Quoin Pharmaceuticals filed 16 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 6, 2026.
- Nov 6, 2026ResultsReleased financial results. Filing
- Nov 4, 2026AgreementQuoin Pharmaceuticals Ltd. entered into a sales agreement with Leerink Partners LLC, pursuant to which the Company may sell, from time to time, American Depositary Shares, each representing 35 of the Company’s ordinary shares, no par value, through Leerink Partners, acting as agent. Filing
- Oct 20, 2026AnnouncementThe Company announced the publication of a peer-reviewed manuscript titled “An Investigational Mechanism-Informed Therapy for Netherton Syndrome: Introduction to QRX003 and a Pediatric Compassionate-Use Case Report” in Dermatology and Therapy. Filing
- Oct 14, 2026AnnouncementThe Company announced that its lead product candidate QRX003 has been granted Orphan Drug Designation in Europe by the EMA for the treatment of Peeling Skin Syndrome. Filing
- Sep 22, 2026AnnouncementThe Company announced that the FDA has granted Fast Track Designation to the Company’s lead asset, QRX003, for the treatment of Peeling Skin Syndrome. Filing
- Sep 10, 2026AnnouncementThe Company announced that the FDA has granted Rare Pediatric Disease (RPD) Designation for the Company’s lead asset, QRX003, for the treatment of Peeling Skin Syndrome (PSS). Filing
- Aug 28, 2026AgreementQuoin Pharmaceuticals Ltd. entered into a Securities Purchase Agreement with several institutional and accredited investors for the issuance and sale in a private placement of securities for gross proceeds of up to approximately $50.0 million, before deducting placement agent fees and other… Filing
- Aug 20, 2026LeadershipChanges to 401(k) Plan Quoin Pharmaceuticals Ltd. held its 2026 Annual General Meeting of Shareholders on August 20, 2026. Filing
- Aug 14, 2026ResultsReleased financial results. Filing
- Jun 23, 2026AnnouncementThe Company announced that the FDA has conditionally approved QYLEKI™ as the proposed brand name for QRX003, the Company’s investigational product candidate for the treatment of Netherton Syndrome. Filing
- Jun 4, 2026AnnouncementThe Company announced that Japan’s MHLW has granted Orphan Drug Designation to QRX003 lotion (4%) for the treatment of Netherton Syndrome, a rare and severe genetic skin disorder for which there are currently no approved treatments. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Mar 26, 2026ResultsReleased financial results. Filing
- Mar 11, 2026AnnouncementThe Company announced that that the FDA has granted Fast Track Designation to QRX003 lotion (4%) for the treatment of Netherton Syndrome, a rare and severe genetic skin disorder for which there are currently no approved treatments. Filing
- Jan 20, 2026AnnouncementThe Company announced that it has filed an application for Breakthrough Medicine Designation with the SFDA for QRX003, its lead investigational, late-stage topical product candidate for the treatment of Netherton Syndrome. Filing
- Nov 17, 2025LeadershipThe Compensation Committee of the Board of Directors of Quoin Pharmaceuticals Ltd. approved forms of award agreements to be used for the grant of stock options to directors and executive officers under the Company’s 2025 Equity Incentive Plan. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Quoin Pharmaceuticals financials
Famous investors that hold QNRX
2 of the 50 well-known investors we track reported holding QNRX in their latest 13F filing. The largest position is Israel Englander's, worth $1M.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 236,227 | $1M | 0.0% | +110% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 20,307 | $92.6K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named QNRX in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | StemPoint Capital LP | 13G | 9.9% |
| Nov 16, 2026 | StemPoint Capital LP | 13G | 9.9% |
| Nov 16, 2026 | Integrated Core Strategies (US) LLC | 13G/A | 5.0% |
| Nov 16, 2026 | Integrated Core Strategies (US) LLC | 13G/A | 5.0% |
| Oct 7, 2026 | Ikarian Capital, LLC | 13G/A | 4.4% |
| Oct 7, 2026 | Ikarian Capital, LLC | 13G/A | 4.4% |
Questions about Quoin Pharmaceuticals Ltd. (QNRX) stock
Are QNRX insiders buying or selling?
In the last 12 months, QNRX insiders reported 3 open-market purchases worth $180K and no sales. The latest trade was on Aug 31, 2026. See every trade.
What is the short interest in QNRX?
As of Oct 30, 2026, 23,705 QNRX shares were sold short, 0.0% of the shares outstanding, up 17.2% from the report before. At the average daily volume of 12,459 shares, buying them all back would take about 1.9 trading days (days to cover). See the history.
Which famous investors hold QNRX?
2 of the 50 well-known investors we track reported QNRX in their latest 13F filing, including Israel Englander, Ken Griffin. The largest position is worth $1M. See all holders.
Executive pay
Quoin Pharmaceuticals's chief executive was paid a total of $1.5M for the year ended Dec 31, 2025, up 7% from $1.4M the year before. In the last 12 months, Quoin Pharmaceuticals's executives and directors bought $180K of stock on the open market and sold none.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.